Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
2
days
Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology
AuthorsJu-Hyun Kim; Seung-Hyuk Shim; Kyung-Jin Min; Jae-Kwan Lee; Chong Woo Yoo; Min-Jung Kwon; Shin-Wha Lee; Jaeman Bae
Affiliations1. Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; 2. Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.; 3. Department of Obstetrics and Gynecology, Korea University Ansan Hospital, Ansan, Korea.; 4. Department of Obstetrics and Gynecology, Korea University Guro Hospital, Seoul, Korea.; 5. Department of Pathology, National Cancer Center, Goyang, Korea.; 6. Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.; 7. Department of Obstetrics and Gynecology, Hanyang University Medical Center, Seoul, Korea.
16
days
The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial
AuthorsGiorgio Bogani; Dong Hoon Suh
Affiliations1. Gynecologic Oncologic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.; 2. Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
81
days
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
AuthorsJung-Yun Lee; Ana Oaknin; Luis Manso; Antonio González-Martín; Iwona Ługowska; Domenica Lorusso; Susana Banerjee; John B. Liao; Chien-Hsing Lu; Naiyarat Prasongsook; Bohuslav Melichar; Chiedozie Anoka; Lindsey Jung; Flavia Michelini; Soham Puvvada; Funda Meric-Bernstam; Vicky Makker
Affiliations1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; 2. Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain.; 3. Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.; 4. Medical Oncology Department and Programme in Solid Tumours CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, Spain.; 5. Center for Excellence in Precision Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.; 6. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; 7. Humanitas San Pio X, Milan, Italy.; 8. Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.; 9. Institute of Cancer Research, London, UK.; 10. Division of Gynecologic Oncology, University of Washington, Seattle, WA, USA.; 11. Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan.; 12. Division of Medical Oncology, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand.; 13. Department of Oncology, Palacky University Medical School and University Hospital, Olomouc, Czech Republic.; 14. Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.; 15. Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.; 16. Translational Medicine, Oncology R&D, AstraZeneca, Barcelona, Spain.; 17. Clinical Development, Late Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.; 18. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; 19. Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; 20. Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
160
days
Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial
AuthorsJie Lin; Qiaoling Wu; Bin Liu; Haixin He; Xinye Guo; Linxia Li; Yu Jiang; Yuxiu Huang; Yingtao Lin; Tongmei He; Xiang Zheng; Sang Li; Lijun Chen; Cuibo Lin; Evangeline Li; Shengtao Zhou; Yang Sun
Affiliations1. Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.; 2. Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; 3. Department of Obstetrics and Gynecology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.; 4. Department of Gynecology and Obstetrics, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.; 5. Clinical Medical Research Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.; 6. Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.; 7. Department of Radiologic Diagnosis, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.; 8. Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA.; 9. Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second Hospital, State Key Laboratory of Biotherapy, and Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China.
193
days
Diagnostic accuracy of the droplet digital PCR POLE mutation test in endometrial cancer: comparison with Sanger sequencing and NGS
AuthorsYung-Taek Ouh; Hyun-Woong Cho; Kyung-Jin Min; Jae-Kwan Lee; Yikyeong Chun; Jin Hwa Hong
Affiliations1. Department of Obstetrics & Gynecology, Korea University Ansan Hospital, Ansan, Korea.; 2. Department of Obstetrics & Gynecology, Korea University Guro Hospital, Seoul, Korea.; 3. Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
222
days
Is restaging surgery quintessential in suspected early-stage epithelial ovarian cancer? An ancillary study of the Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3002)
AuthorsJung Chul Kim; Eun Jung Yang; A Jin Lee; Woo Yeon Hwang; Suk-Joon Chang; Hee Seung Kim; Namkyeong Kim; Tae Wook Kong; Eun Ji Lee; Joo-Hyuk Son; Dong Hoon Suh; Seung-Hyuk Shim; Eun Ji Nam
Affiliations1. Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; 2. Department of Obstetrics and Gynecology, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.; 3. Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.; 4. Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.; 5. Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.; 6. Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
238
days
P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis
AuthorsHang Zhou; Yu Dai; Hua Zhang; Yuan Yang; Ruoji Pi; Lingling Zhu; Wen Chen
Affiliations1. Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; 2. The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.; 3. Mianyang Maternal and Child Health Care Hospital, Mianyang, China.
244
days
Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset
AuthorsWen-Shiung Liou; Angel Chao; Bor-Ching Sheu; Lian-Shung Yeh; Chen-Hsuan Wu
Affiliations1. Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.; 2. Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou, Taiwan.; 3. Chang Gung University College of Medicine, Taoyuan, Taiwan.; 4. Gynecologic Cancer Research Center, Chang Gung Memorial Hospital at Linkou and Taoyuan, Taiwan.; 5. Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.; 6. College of Medicine, China Medical University, Taichung, Taiwan.; 7. Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan.; 8. Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
323
days
Comparative outcomes of adjuvant chemotherapy alone versus combined chemotherapy and radiation therapy in patients with stage III endometrial cancer: a propensity score matching study
AuthorsKhemanat Khemworapong; Janjira Petsuksiri; Atthapon Jaishuen; Pittaya Dankulchai; Kullathorn Thephamongkol; Jiraporn Setakornnukul
Affiliations1. Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; 2. Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
370
days
LKB1 attenuates the transport activity of GLUT1 by regulating the alternative splicing of PKM1/PKM2 in cervical cancer
AuthorsMingzhe Wu; Yaoxing Guo; Jinghua Yang; Enhua Wang; Hong-Tao Xu; Guang-Ping Wu; Huanyu Zhao
Affiliations1. Department of Gynecology, The First Hospital of China Medical University, Shenyang, China.; 2. Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, China.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days